PT  - JOURNAL ARTICLE
AU  - Khaldoon O. Al-Nosairy
AU  - Hagen Thieme
AU  - Michael B. Hoffmann
TI  - Diagnostic performance of multifocal photopic negative response, pattern electroretinogram and optical coherence tomography in glaucoma
AID  - 10.1101/2020.03.18.20034785
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.18.20034785
4099  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20034785.short
4100  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20034785.full
AB  - Objectives To optimize stimulation parameters for electroretionographic recordings of the multifocal photopic negative response (mfPhNR) for the detection of glaucoma and to compare the diagnostic accuracy of electrophysiological, structural and functional measures of glaucoma.Methods In 24 healthy controls, 10 glaucoma suspects (GLAS) and 16 glaucoma participants (GLAG), mfPhNR for 6 different stimulation rates were assessed to compare their discrimination performance. Subsequently, a cross-modal comparison of the mfPhNR/b-wave ratio was performed with pattern electroretinogram (PERG), and peripapillary retinal nerve fiber layer (pRNFL) thickness. These analyses were based on area under curves (AUC) obtained from receiver-operating-characteristics (ROC) analyses and step-wise regression analyses.Results Compared to the other mfPhNR-conditions, the PhNR/b-wave ratio for the fastest stimulation condition had the highest AUC for GLAS(0.84, P = 0.008, 95%CI: 0.71-0.98); the other modalities, i.e., PERG-amplitude and pRNFL had AUCs of 0.77, and 0.74 respectively. pRNFL was the significant predictor for mfPhNR/b-wave ratio [t (48) = 4, P 0.0002].Conclusions Fast mfPhNR protocols outperform other mf-protocols in the identification of glaucomatous damage especially for GLAS and thus aid the early detection of glaucoma.Significance mfPhNR recordings might serve as surrogate marker of ganglion cell dysfunction especially in glaucoma suspects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement (No. 675033) to Michael B. Hoffmann.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request.